Comparing a new long-lasting injection to standard one for DME
Treatments studied
Part of Eyes & vision clinical trials.
This phase 3 trial tests a new long-acting injection (EYP-1901) against a standard one (aflibercept) for people with diabetic macular edema. Both treatments are given as eye injections, and the goal is to see if the new drug works as well and may require fewer injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have swelling in the central part of your retina caused by diabetes (diabetic macular edema).
- Your vision in the study eye is between 20/200 and 20/32 (moderate to fairly good vision).
- If you've had eye injections before, it must have been at least 3 months since your last one.
- Your other eye must have vision of 20/250 or better.
- This study compares a new long-lasting injection (EYP-1901) to a standard treatment (aflibercept).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This study compares a new medication, tabirafusp tedromer, to an existing treatment, aflibercept, for people with diabetic macular edema (swelling in the back of the eye from diabetes). It may help if your DME hasn't improved or you're looking for a new option.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This study tests whether a new drug (AVT29) is as safe and effective as the standard treatment Eylea HD for people with diabetic macular edema (DME) — a condition where fluid builds up in the back of the eye due to diabetes. If you have vision loss from DME and haven't had anti-VEGF injections before, you may be able to join.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.